Smith & Nephew SNATS (SNN) – Research Analysts’ Recent Ratings Updates

A number of firms have modified their ratings and price targets on shares of Smith & Nephew SNATS (NYSE: SNN) recently:

• 8/16/2026 – Smith & Nephew SNATS was downgraded by Wall Street Zen from “buy” to “hold”.
• 8/8/2026 – Smith & Nephew SNATS was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 8/7/2026 – Smith & Nephew SNATS was downgraded by Zacks Research from “hold” to “strong sell”.
• 8/6/2026 – Smith & Nephew SNATS had its “neutral” rating reaffirmed by JPMorgan Chase & Co..
• 8/5/2026 – Smith & Nephew SNATS had its “overweight” rating reaffirmed by Morgan Stanley.
• 8/5/2026 – Smith & Nephew SNATS was downgraded by Barclays PLC from “equal weight” to “underweight”.
• 7/4/2026 – Smith & Nephew SNATS was upgraded by Wall Street Zen from “buy” to “strong-buy”.

Smith & Nephew SNATS Announces Dividend

The company also recently declared a dividend, which will be paid on Friday, November 6th. Investors of record on Friday, October 2nd will be paid a $0.312 dividend. This represents a yield of 205.0%. The ex-dividend date is Friday, October 2nd.

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.